GMS 6551 Final Exam Questions and Answers A+ Graded (2025).

GMS 6551 Final Exam Questions and
Answers A+ Graded (2025)




Drugs .usually .target: .- .CORRECT .ANSWER-non-human .protein

Natural .products .include .- .CORRECT .ANSWER-plants, .algae, .bacteria, .fungi

Chemical .banks .include .- .CORRECT .ANSWER-synthetic .compounds .that
.number .in .thousands .or .millions


Rational .drug .design .- .CORRECT .ANSWER-utilizes .side .effects .from .another
.drug .to .treat .another .disease .by .modifying .a .natural .ligand


Computer .aided .drug .design .(molecular .docking) .- .CORRECT .ANSWER-take
.crystal .structure .of .target .protein, .look .at .it .in .3D .program. .computer .program
.calculates .chemical .attraction.


Structure .Activity .Relationships .- .CORRECT .ANSWER-Use .organic .chemistry .to
.add .functional .groups, .test .new .compounds, .take .best .and .add .more .functional
.grounds, .then .begin .clinical .trials


Drug .- .CORRECT .ANSWER-any .substance .that .interacts .and .modulates .a .living
.system


Agonist .- .CORRECT .ANSWER-drug .that .activates .biological .response

Antagonist .- .CORRECT .ANSWER-drug .that .inhibits .biological .response

Nomenclature .- .CORRECT .ANSWER-chemical .name .given .based .on .chemical
.structure


Non-generic .name .- .CORRECT .ANSWER-name .given .based .on .chemical .or
.pharmacologic .class


Proprietary .name .- .CORRECT .ANSWER-name .given .at .marketable .point

FDA-approved .beta .blockers .- .CORRECT .ANSWER-end .in .-lol

, Drugs .classified .based .on .chemical .properties .- .CORRECT .ANSWER-
benzodiazepines, .sulfonamides

Drugs .classified .based .on .mechanism .of .action .- .CORRECT .ANSWER-ACE
.inhibitors, .calcium .channel .blockers, .carbonic .anhydrase .inhibitors


Drugs .classified .based .on .disease .or .condition .used .to .treat .- .CORRECT
.ANSWER-Analgesics, .antidepressants, .antihypertensives


Drugs .classified .based .on .abuse .potential .- .CORRECT .ANSWER-Class .I, .II, .III,
.IV


Flumencinol .- .CORRECT .ANSWER-treatment .of .hyperbilirubinemia .in .newborn
.infants .unresponsive .to .phototherapy


Antithrombin .III .- .CORRECT .ANSWER-treatment .of .patients .with .hereditary
.antithrombin .III .deficiency .in .connection .with .surgical .or .obstetrical .procedures
.or .when .they .suffer .from .thromboembolism


gancyclovir .- .CORRECT .ANSWER-treat .CMV .in .immunocompromised .patients

EGF .- .CORRECT .ANSWER-wound .healing

Zidovudine/AZT .- .CORRECT .ANSWER-treat .AIDS

Succimer .- .CORRECT .ANSWER-treat .lead .poisoning

Somatrem, .somatropin .- .CORRECT .ANSWER-treating .growth .hormone
.deficiency


acetylcysteine .- .CORRECT .ANSWER-treat .acetaminophen .overdose

Glatiramer .acetate .- .CORRECT .ANSWER-treat .multiple .sclerosis

Class .I .controlled .substances .- .CORRECT .ANSWER-High .abuse .potential
.(heroin, .LSD, .marijuana) .cannot .be .prescribed


Class .II .controlled .substances .- .CORRECT .ANSWER-High .abuse .potential, .no
.refills .(morphine, .amphetamine, .high .dose .codeine)


Class .III .controlled .substances .- .CORRECT .ANSWER-Moderate .abuse .potential
.(ketamine, .low .dose .codeine) .5 .max .refills .within .6 .months


Class .IV .controlled .substances .- .CORRECT .ANSWER-Low .abuse .potential
.(benzodiazepines) .5 .refills .max .within .6 .months


Class .V .controlled .substances .- .CORRECT .ANSWER-Lowest .abuse .potential
.(dephenoxylate)